In August 2o26, the Arizona Bioindustry Association (AZBio) joined over 11,ooo stakeholders from across the country in submitting comments on the CMS Proposed Rule on Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program. On November 5, 2026, CMS published the final rule. Continue reading
Category Archives: AZBio News
BIO, Biocom, and California Life Sciences Sue to Block CMS GLOBE Rule
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.Continue reading
TGen Scientists Use AlphaFold3 to Predict Complex Immune Interactions
New AI-driven approach could help researchers better understand how the immune system responds to infections and cancer
AZBio Member Spotlight – Airobes LLC
Based in Arizona, Airobes is working to make manufacturing of AI-designed proteins faster, cheaper, and more sustainable, helping unlock the next generation of biologics and therapeutics.Continue reading
Arizona Bioscience on the Rise: Highlights from the 2026 TEConomy/BIO Report
Arizona’s bioscience industry isn’t just growing. It’s outpacing the nation.
The 2026 edition of The U.S. Bioscience Economy from TEConomy Partners and the Biotechnology Innovation Organization (BIO) gives us a fresh look at how Arizona stacks up. The short version: since 2021, our bioscience workforce has grown 13.4 percent, nearly twice the national rate of 7.0 percent. Here’s what’s driving that momentum.Continue reading
U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact.
BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Oct. 28, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. commercial launch of the BD® Liverty™ TIPS Stent Graft, advancing portal hypertension care by giving physicians greater flexibility to tailor treatment to each patient’s hemodynamic needs. The next generation transjugular intrahepatic portosystemic shunt (TIPS) system is designed to provide physicians with deployment accuracy and control, and the flexibility to tailor treatment based on individual patient anatomy, disease progression and clinical goals. The product enters the U.S. market with established clinical and physician experience in Europe and is supported by the six-month interim results from the 177 patient, prospective, multi-center ARCH clinical study, the first and only IDE study with small TIPS diameter (6-7 mm) clinical data.Continue reading
Treasury Issues Proposed Rule to Implement Comprehensive Outbound Investment National Security Act
WASHINGTON– The U.S. Department of the Treasury (Treasury) today issued a Notice of Proposed Rulemaking (NPRM) to propose updates to the Outbound Investment Security Program (OISP) based on direction from Congress in the Comprehensive Outbound Investment Security (COINS) Act, passed as part of the Fiscal Year 2026 National Defense Authorization Act. The COINS Act codifies the U.S. Government’s approach to regulating certain outbound investments by U.S. persons and builds upon Treasury’s existing OISP.
AZBio Member Spotlight – Jazz Pharmaceuticals
Based globally with a presence in Arizona, Jazz Pharmaceuticals is working to change what is possible for people living with rare and serious diseases, particularly in areas where treatment options are limited and the consequences for patients and families can be profound.Continue reading
Senphonix Receives National Institutes of Health Grant to Advance SleeveSense, a Continuous, Long-Term Vitals Monitoring Platform
NIH SBIR funding from the National Heart, Lung, and Blood Institute advances the secure data platform behind a wearable designed to ease the burden of manual vital-signs checks and to support better-informed care whether in the hospital or at home.Continue reading